大行评级｜大摩：微升中国人寿目标价至25.7港元 上调2025至27年每股盈测

Group 1 - Morgan Stanley updated its model following China Life's half-year performance report, raising the earnings per share estimates for 2025 to 2027 by 13.1%, 1%, and 1.9% respectively, primarily benefiting from the stock market rise and steady sales growth in the fiscal year 2025 [1] - With improvements in profit margins, the new business value forecasts for each fiscal year increased by 6.6%, 8.1%, and 8.5% respectively [1] - Morgan Stanley slightly raised the target price for China Life's H-shares from HKD 25 to HKD 25.7, maintaining an "Overweight" rating [1]